Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiophenytoin SCHEMBL1685397 | 0.76 | CYP2C9 (0.64) | CYP2C9MAPTBLMPMP22ALDH1A1 | |
| SCHEMBL598851 | 0.73 | MAPT (0.41) | CYP2C9MAPTBLMPMP22ALDH1A1 | |
| SCHEMBL3299636 | 0.73 | ALDH1A1 (0.47) | CYP2C9MAPTBLMPMP22ALDH1A1 | |
| SCHEMBL30457291 | 0.71 | LMNA (0.53) | CYP2C9MAPTBLMPMP22ALDH1A1 | |
| SCHEMBL5466685 | 0.64 | KMT2A (0.64) | MAPTKMT2AMEN1MMP2MMP9 | |
| SCHEMBL17294181 | 0.64 | MAPT (0.41) | CYP2C9MAPTBLMPMP22ALDH1A1 | |
| SCHEMBL9717767 | 0.63 | ALDH1A1 (0.37) | CYP2C9MAPTBLMPMP22ALDH1A1 | |
| SCHEMBL7488088 | 0.63 | CYP2C9 (0.42) | CYP2C9MAPTBLMPMP22ALDH1A1 | |
| SCHEMBL21379715 | 0.62 | ALDH1A1 (0.43) | CYP2C9MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL14077803 | 0.61 | ALDH1A1 (0.40) | CYP2C9MAPTBLMPMP22ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080305074-A1 | Stem cell factor | AMGEN INC. (US) | 2008-12-11 | — | — | US | disclosed |
| EP-0992579-B1 | Stem cell factor | AMGEN INC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070071714-A1 | Stem cell factor | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-7144731-B2 | SCF antibody compositions and methods of using the same | AMGEN INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20050261175-A1 | SCF antibody compositions and methods of using the same | BIOVITRUM AB (PUBL) (SE) | 2005-11-24 | — | — | US | disclosed |
| US-6967029-B1 | Method for increasing hematopoietic progenitor cells by stem cell factor | AMGEN INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050080250-A1 | Methods of stimulating growth of stromal cells in a human | ZSEBO KRISZTINA M (US) | 2005-04-14 | — | — | US | disclosed |
| US-6852313-B1 | Method of stimulating growth of melanocyte cells by administering stem cell factor | AMGEN INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-6841147-B2 | Stem cell factor compositions | AMGEN, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| US-20040181044-A1 | Method of stimulating growth of epithelial cells by administering stem cell factor | ZSEBO KRISZTINA M (US) | 2004-09-16 | — | — | US | disclosed |
| US-5716934-A | TARGET SPECIFIC RECEPTOR BINDING PROTEIN; CANCER DIAGNOSIS | AMGEN INC. (US) | 1998-02-10 | — | — | US | disclosed |
| US-5650504-A | Nucleic acids encoding eck receptor ligands | AMGEN INC. (US) | 1997-07-22 | — | — | US | disclosed |
| WO-1996036713-A2 | ECK RECEPTOR LIGANDS | AMGEN INC. (US) | 1996-11-21 | — | — | WO | disclosed |
| EP-0676470-A1 | Stem cell factor | AMGEN INC. (US) | 1995-10-11 | — | — | EP | disclosed |
| WO-1994011020-A1 | ECK RECEPTOR LIGANDS | AMGEN INC. (US) | 1994-05-26 | — | — | WO | disclosed |
| EP-0597503-A2 | ECK receptor ligands | AMGEN INC. (US) | 1994-05-18 | — | — | EP | disclosed |
| WO-1991005795-A1 | STEM CELL FACTOR | AMGEN INC. (US) | 1991-05-02 | — | — | WO | disclosed |
| EP-0423980-A1 | Stem cell factor | AMGEN INC. (US) | 1991-04-24 | — | — | EP | disclosed |
| US-4607023-A | DIURETICS, POLYPEPTIDES | L'INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL (CA) | 1986-08-19 | — | — | US | disclosed |
| EP-0140731-A2 | Natriuretic factors | INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL (CA) | 1985-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305074-A1 | Stem cell factor | KIT, CBFB, ILF2 | CYP2C9 4851/4885MAPT 4693/4885BLM 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.